Company profile
AMYLYX PHARMACEUTICALS, INC.
NASDAQ:AMLXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RELYVRIO | approved | $0.0M*Q4 2025 | 9 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04516096 | phase2_3 | completed | 2020-11-22 | 2022-12-30 | Amylyx Pharmaceuticals Inc. | A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) |
| NCT06122662 | phase2_3 | completed | 2023-12-21 | 2025-09-30 | Amylyx Pharmaceuticals Inc. | AMX0035 and Progressive Supranuclear Palsy |
| NCT05676034 | phase2 | active_not_recruiting | 2023-03-03 | 2024-07-23 | Amylyx Pharmaceuticals Inc. | AMX0035 in Adult Patients With Wolfram Syndrome |
| NCT03127514 | phase2 | completed | 2017-06-22 | 2019-09-25 | Amylyx Pharmaceuticals Inc. | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) |
| NCT06665165 | phase1 | recruiting | 2025-04-07 | 2027-02-01 | Amylyx Pharmaceuticals Inc. | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 216660 | 2022-09-29 | NDA | AMYLYX PHARMACEUTICALS INC | |||||
Loading… | ||||||||